619 related articles for article (PubMed ID: 27683798)
41. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
42. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
43. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
Colombel JF; Ungaro RC; Sands BE; Siegel CA; Wolf DC; Valentine JF; Feagan BG; Neustifter B; Kadali H; Nazarey P; James A; Jairath V; Qasim Khan RM
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1487-1496.e12. PubMed ID: 37743037
[TBL] [Abstract][Full Text] [Related]
44. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
[TBL] [Abstract][Full Text] [Related]
45. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
Feagan BG; Lasch K; Lissoos T; Cao C; Wojtowicz AM; Khalid JM; Colombel JF
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):130-138.e7. PubMed ID: 29857145
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
[TBL] [Abstract][Full Text] [Related]
47. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
48. Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
D'Haens G; Rosario M; Polhamus D; Dirks NL; Chen C; Kisfalvi K; Agboton C; Vermeire S; Feagan BG; Sandborn WJ
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):403-412. PubMed ID: 38441048
[TBL] [Abstract][Full Text] [Related]
49. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
Danese S; Subramaniam K; Van Zyl J; Adsul S; Lindner D; Roth J; Vermeire S
Aliment Pharmacol Ther; 2021 Jan; 53(2):265-272. PubMed ID: 33210333
[TBL] [Abstract][Full Text] [Related]
50. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
51. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
Feagan BG; Sandborn WJ; Colombel JF; Byrne SO; Khalid JM; Kempf C; Geransar P; Bhayat F; Rubin DT
J Crohns Colitis; 2019 Jan; 13(1):50-57. PubMed ID: 30203005
[TBL] [Abstract][Full Text] [Related]
52. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
53. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
[TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
55. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
[TBL] [Abstract][Full Text] [Related]
56. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
[No Abstract] [Full Text] [Related]
57. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
Pintar Š; Hanžel J; Drobne D; Koželj M; Kurent T; Smrekar N; Novak G
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399583
[No Abstract] [Full Text] [Related]
58. Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach.
Zargar AA
Drug Dev Res; 2024 Jun; 85(4):e22220. PubMed ID: 38845229
[TBL] [Abstract][Full Text] [Related]
59. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
60. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
